Literature DB >> 5042371

The absorption and metabolism of dibromodulcitol in patients with advanced cancer.

M A Belej, W M Troetel, A J Weiss, J E Stambaugh, R W Manthei.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 5042371     DOI： 10.1002/cpt1972134563

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  3 in total

1.  Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma.

Authors:  D A Amato; H Bruckner; D Guerry; A Ash; G Falkson; E C Borden; R H Creech; E D Savlov; T J Cunningham
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

2.  Comparison of the cytotoxic activities of chemotherapeutic drugs using a human bladder cancer cell line.

Authors:  P J Hepburn; R T Oliver; P A Riley; B T Hill; J R Masters
Journal:  Urol Res       Date:  1985

3.  Pharmacokinetic study in a phase I trial with an alkylating agent, diacetyldianhydrogalactitol (DADAG).

Authors:  V Erdélyi-Tóth; S Kerpel-Fronius; B Kanyár; S Eckhardt
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.